NuVasive Inc

NuVasive — Q2 2017 Earnings Presentation

14 slides from NuVasive's earnings presentation, Jul 27, 2017

  1. Slide 1: Q2 2017 Results

    Exhibit 99.4 Q2 2017 Results Supplemental Presentation to Earnings Press Release July 27, 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements NuVasive cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could caus

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, non-cash purchase accounting adjustments on acq

  4. Slide 4: Q2 2017 Performance

    Q2 2017 Performance Reported year-over-year revenue growth of 10.3% to $260.6 million, or 10.7% on a constant currency basis. Delivered GAAP operating profit margin of 11.4%; non-GAAP operating profit margin of 16.3%. Drove GAAP diluted earnings per share of $0.22; non-GAAP diluted EPS up 15.0% to $

  5. Slide 5: Second Quarter 2017 Revenue Highlights

    Second Quarter 2017 Revenue Highlights U.S. SPINAL HARDWARE U.S. SURGICAL SUPPORT INTERNATIONAL Includes All Implants, Fixation, Includes Biologics, IOM Includes Puerto Rico MAGEC® & PRECICE ® Services & Disposables 3.0% 18.7% 26.0% * in 2Q17 in 2Q17 in 2Q17 Key Performance Factors Key Performance F

  6. Slide 6: Second Quarter 2017 P&L Performance

    Second Quarter 2017 P&L Performance 2Q17 2Q17 YoY Actuals Performance Factors Non-GAAP Measures 330 bps negatively impacted by lower gross margin profile of the Biotronic business (~280 bps); inventory Gross Margin 74.5% inefficiencies due to transfer of production to new manufacturing facility 350

  7. Slide 7: Strong History of Growth and Profitability

    Strong History of Growth and Profitability DISCIPLINED EXECUTION OF STRATEGY DRIVES EXCEPTIONAL RESULTS Global Revenue Non-GAAP Operating (In Millions) Profit Margin ~570 Basis Point $1,065* ~17.1%* Improvement $962.1 16.1% 15.4% $811.1 11.4% $762.4 2014 2015 2016 2017E 2014 2015 2016 2017E 7 * NuVa

  8. Slide 8: Reducing Surgical Radiation

    Reducing Surgical Radiation Software that enables O.R. staff to Takes low-quality, low-radiation reduce their levels of exposure to images and improves them to look surgical radiation like conventional full dose images Will help increase adoption of A foundational element of our multi- minimally inv

  9. Slide 9: Launching LessRay

    Launching LessRay® Targeted launch in September 2017 Revenue recognition expected to begin in Q417 Priced with options, inducing capital purchase and leasing option with service and support agreements Focused selling for use in spine surgery and over time will address additional markets where radiat

  10. Slide 10: Investment in U.S. Manufacturing

    Investment in U.S. Manufacturing World-class, Manufacturing HQ in West Carrollton Nearly Complete New ‘all digital’, 180,000 sq. ft. facility is on-line and WEST CARROLLTON, supporting select implants and instruments OHIO Produced 160,000+ parts out of facility in Q2, doubling the parts from Q1 Hiri

  11. Slide 11: Full Year 2017 Financial Performance Guidance

    Full Year 2017 Financial Performance Guidance* FY17 Guidance Performance Drivers Revenues • As reported ~$1.065B, ~11.1% YoY growth^ ~$61M full year of Biotronic contribution; ~$4M currency headwind • U.S. Spinal Hardware ~7% YoY growth Strong expected lumbar, cervical and NSO product performance •

  12. Slide 12: 2H 2017 Performance Drivers

    2H 2017 Performance Drivers STRATEGIC PRIORITIES ALIGNED TO DELIVER CONTINUED GROWTH New product launches International executing and leading spine on all cylinders innovation roadmap Entering new markets: Success in adding - trauma new, leading surgeons - radiation reduction New sales reps hired la

  13. Slide 13: Why Invest in NuVasive

    Why Invest in NuVasive RELENTLESS FOCUS ON DRIVING SHAREHOLDER VALUE #1 #2 #3 #4 #5 Grow Expand Tax Rate EPS Free Cash Revenues Operating + Improvement Growth Flow EBITDA Margins Growing Long-term non-GAAP Drive change in tax Optimizing tax Set to generate revenues at operating profit rate from high

  14. Slide 14: Xl NUVASIVE

    oN | Xl NUVASIVE

NuVasive — Q2 2017 Earnings Presentation on 6ix